Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT041 in Pancreatic Cancer After Adjuvant Chemotherapy
NCT05911217Phase 1Recruiting
- Sponsor
- CARsgen Therapeutics
- Start
- Jul 2023
- Primary completion
- Dec 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of satricabtagene autoleucel in pancreatic ductal adenocarcinoma (PDAC), sponsored by CARsgen Therapeutics. Primary endpoint: Disease Free Survival at 18 months. Started Jul 2023; status: recruiting.
02
Drugs
satricabtagene autoleucel
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05911217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05911217.